Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220809689> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W4220809689 endingPage "2027" @default.
- W4220809689 startingPage "2020" @default.
- W4220809689 abstract "The RENOWNED study investigated the treatment patterns, real-world effectiveness and safety of ranibizumab in Taiwanese patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab 0.5 mg in accordance with the first reimbursement scheme effective from 2012 to 2014. This study was a Phase IV, 12-month, open-label, prospective, observational study conducted in Taiwan. Patients with visual impairment due to nAMD initiating treatment with ranibizumab 0.5 mg were included. The primary endpoint was mean change in best-corrected visual acuity (BCVA) from Baseline at Month 3. Overall, 202 patients with nAMD were included. Mean (standard deviation [SD]) BCVA Early Treatment Diabetic Retinopathy Study letters improved from Baseline (49.6 [21.5] letters) at Month 3 (+4.9 [11.8], P < 0.0001), and at Month 12 (+3.5 [14.1], P = 0.0043). The proportion of patients with nAMD who lost ≥5 letters at Months 3 and 12 was 13.6% (n = 27) and 26.6% (n = 37), respectively. Mean (SD) central retinal thickness decreased from Baseline (320.1 [127.2] μm) with a mean reduction of 49.1 (107.3) μm at Month 3 (P < 0.0001), but was not significant at Month 12 with a mean reduction of 11.6 (115.6) μm (P = 0.2861). Mean (SD) number of ranibizumab injections over 12 months was 3.1 (1.0). A mean treatment interval of 109.5 days was observed between the third and fourth injections. After limited reimbursed ranibizumab injections, 43.8% patients received other treatments. The safety findings are consistent with previous studies. Ranibizumab 0.5 mg treatment for 12 months under real-world settings improved visual outcomes in Taiwanese patients with nAMD." @default.
- W4220809689 created "2022-04-03" @default.
- W4220809689 creator A5005138092 @default.
- W4220809689 creator A5024064960 @default.
- W4220809689 creator A5043123251 @default.
- W4220809689 creator A5045508161 @default.
- W4220809689 creator A5048649275 @default.
- W4220809689 creator A5053084323 @default.
- W4220809689 creator A5074872629 @default.
- W4220809689 creator A5087359162 @default.
- W4220809689 date "2022-10-01" @default.
- W4220809689 modified "2023-10-17" @default.
- W4220809689 title "Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan – Results from the 12-month, observational RENOWNED study" @default.
- W4220809689 cites W1481978003 @default.
- W4220809689 cites W1976685144 @default.
- W4220809689 cites W2003324689 @default.
- W4220809689 cites W2006988015 @default.
- W4220809689 cites W2016030826 @default.
- W4220809689 cites W2027374419 @default.
- W4220809689 cites W2036832061 @default.
- W4220809689 cites W2057628931 @default.
- W4220809689 cites W2068742492 @default.
- W4220809689 cites W2104421727 @default.
- W4220809689 cites W2124415048 @default.
- W4220809689 cites W2134161293 @default.
- W4220809689 cites W2789226077 @default.
- W4220809689 cites W2805603897 @default.
- W4220809689 doi "https://doi.org/10.1016/j.jfma.2022.02.005" @default.
- W4220809689 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35279311" @default.
- W4220809689 hasPublicationYear "2022" @default.
- W4220809689 type Work @default.
- W4220809689 citedByCount "4" @default.
- W4220809689 countsByYear W42208096892022 @default.
- W4220809689 countsByYear W42208096892023 @default.
- W4220809689 crossrefType "journal-article" @default.
- W4220809689 hasAuthorship W4220809689A5005138092 @default.
- W4220809689 hasAuthorship W4220809689A5024064960 @default.
- W4220809689 hasAuthorship W4220809689A5043123251 @default.
- W4220809689 hasAuthorship W4220809689A5045508161 @default.
- W4220809689 hasAuthorship W4220809689A5048649275 @default.
- W4220809689 hasAuthorship W4220809689A5053084323 @default.
- W4220809689 hasAuthorship W4220809689A5074872629 @default.
- W4220809689 hasAuthorship W4220809689A5087359162 @default.
- W4220809689 hasConcept C118487528 @default.
- W4220809689 hasConcept C126322002 @default.
- W4220809689 hasConcept C134018914 @default.
- W4220809689 hasConcept C141071460 @default.
- W4220809689 hasConcept C188816634 @default.
- W4220809689 hasConcept C203092338 @default.
- W4220809689 hasConcept C23131810 @default.
- W4220809689 hasConcept C2776403814 @default.
- W4220809689 hasConcept C2776694085 @default.
- W4220809689 hasConcept C2777802072 @default.
- W4220809689 hasConcept C2778257484 @default.
- W4220809689 hasConcept C2779829184 @default.
- W4220809689 hasConcept C2781100027 @default.
- W4220809689 hasConcept C2781359195 @default.
- W4220809689 hasConcept C535046627 @default.
- W4220809689 hasConcept C555293320 @default.
- W4220809689 hasConcept C71924100 @default.
- W4220809689 hasConceptScore W4220809689C118487528 @default.
- W4220809689 hasConceptScore W4220809689C126322002 @default.
- W4220809689 hasConceptScore W4220809689C134018914 @default.
- W4220809689 hasConceptScore W4220809689C141071460 @default.
- W4220809689 hasConceptScore W4220809689C188816634 @default.
- W4220809689 hasConceptScore W4220809689C203092338 @default.
- W4220809689 hasConceptScore W4220809689C23131810 @default.
- W4220809689 hasConceptScore W4220809689C2776403814 @default.
- W4220809689 hasConceptScore W4220809689C2776694085 @default.
- W4220809689 hasConceptScore W4220809689C2777802072 @default.
- W4220809689 hasConceptScore W4220809689C2778257484 @default.
- W4220809689 hasConceptScore W4220809689C2779829184 @default.
- W4220809689 hasConceptScore W4220809689C2781100027 @default.
- W4220809689 hasConceptScore W4220809689C2781359195 @default.
- W4220809689 hasConceptScore W4220809689C535046627 @default.
- W4220809689 hasConceptScore W4220809689C555293320 @default.
- W4220809689 hasConceptScore W4220809689C71924100 @default.
- W4220809689 hasIssue "10" @default.
- W4220809689 hasLocation W42208096891 @default.
- W4220809689 hasLocation W42208096892 @default.
- W4220809689 hasOpenAccess W4220809689 @default.
- W4220809689 hasPrimaryLocation W42208096891 @default.
- W4220809689 hasRelatedWork W1963802826 @default.
- W4220809689 hasRelatedWork W1992528831 @default.
- W4220809689 hasRelatedWork W2024548441 @default.
- W4220809689 hasRelatedWork W2042612903 @default.
- W4220809689 hasRelatedWork W2054981704 @default.
- W4220809689 hasRelatedWork W2068871928 @default.
- W4220809689 hasRelatedWork W2069923377 @default.
- W4220809689 hasRelatedWork W2139018208 @default.
- W4220809689 hasRelatedWork W2769959318 @default.
- W4220809689 hasRelatedWork W2599281049 @default.
- W4220809689 hasVolume "121" @default.
- W4220809689 isParatext "false" @default.
- W4220809689 isRetracted "false" @default.
- W4220809689 workType "article" @default.